“…Studies have demonstrated significant differences in metrics derived from graphs of brain networks between diseased and healthy groups as well as in normal development (Supekar et al, 2009), for example, in multiple sclerosis (He et al, 2009), Alzheimer's (Buckner et al, 2009;Stam et al, 2009), Parkinson's (Göttlich et al, 2013), epilepsy (Quraan et al, 2013), and body dysmorphic disorder (Arienzo et al, 2013) [for reviews see Bassett and Bullmore (2009);Menon (2011);Wang et al (2010)], and have offered various interpretations of these findings. With this wave of positive results, some authors have suggested the use of graph metrics as surrogate markers in clinical trials (Petrella, 2011) and even suggested that they have potential as diagnostic tools (Quraan et al, 2013;Schoonheim et al, 2013). However, such applications Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, United Kingdom.…”